Curaleaf Holdings has been approved as a Clinical Registrant in Pennsylvania by the Commonwealth’s Department of Health, Office of Medical Marijuana. Under this designation, the Company will be permitted to open a cultivation and processing facility and up to six dispensaries, under the Commonwealth’s medical marijuana research program.
"As a Clinical Registrant, Curaleaf will support research initiatives into the potential medical benefits of cannabis by providing medical cannabis, expertise and distribution to patients participating in studies," the team with the company explains.
In announcing the awards of the clinical registrant licenses, Dr. Rachel Levine of the Pennsylvania Department of Health remarked; “Pennsylvania remains on the forefront for clinical research on medical cannabis. This research is essential to providing physicians with more evidence-based research to make clinical decisions for their patients. It is the cornerstone of our program and the key to our clinically based, patient-focused program for those suffering with cancer, PTSD and other serious medical conditions.”
Joe Lusardi, Chief Executive Officer of Curaleaf, said, “We thank the Pennsylvania Department of Health for approving Curaleaf to participate in this vital research program. The Pennsylvania State Legislature mandated research as a component of its medical cannabis program, setting it apart from the rest of the nation. Curaleaf has always been focused on high-quality cannabis products, as well as superior patient care and education. We look forward to contributing to medical research that will ultimately benefit not only the residents of the Commonwealth, but the entire country.”
For more information:
Curaleaf
(781) 451-0150
301 Edgewater Place
Suite 405
Wakefield, MA 01880
info@curaleaf.com
curaleaf.com